Regulation FD Disclosure Form 8 K

After market close on October 9, 2024, the management team of ADMA Biologics, Inc. (the "Company"), in speaking with its analysts regarding a change to the Company's auditors as described in the Company's Current Report on Form 8-K filed on October 9, 2024, stated that there is no anticipated impact to the Company's previously provided 2024-2025 financial guidance as a result of the auditor transition process.